全文获取类型
收费全文 | 19120篇 |
免费 | 1563篇 |
国内免费 | 530篇 |
专业分类
耳鼻咽喉 | 235篇 |
儿科学 | 215篇 |
妇产科学 | 263篇 |
基础医学 | 1833篇 |
口腔科学 | 1217篇 |
临床医学 | 2007篇 |
内科学 | 2146篇 |
皮肤病学 | 586篇 |
神经病学 | 1003篇 |
特种医学 | 981篇 |
外国民族医学 | 2篇 |
外科学 | 3624篇 |
综合类 | 2582篇 |
预防医学 | 1061篇 |
眼科学 | 293篇 |
药学 | 1545篇 |
10篇 | |
中国医学 | 860篇 |
肿瘤学 | 750篇 |
出版年
2024年 | 19篇 |
2023年 | 315篇 |
2022年 | 463篇 |
2021年 | 825篇 |
2020年 | 752篇 |
2019年 | 721篇 |
2018年 | 681篇 |
2017年 | 694篇 |
2016年 | 730篇 |
2015年 | 707篇 |
2014年 | 1109篇 |
2013年 | 1155篇 |
2012年 | 942篇 |
2011年 | 1157篇 |
2010年 | 1043篇 |
2009年 | 852篇 |
2008年 | 870篇 |
2007年 | 916篇 |
2006年 | 806篇 |
2005年 | 722篇 |
2004年 | 601篇 |
2003年 | 567篇 |
2002年 | 423篇 |
2001年 | 347篇 |
2000年 | 336篇 |
1999年 | 312篇 |
1998年 | 274篇 |
1997年 | 232篇 |
1996年 | 219篇 |
1995年 | 255篇 |
1994年 | 234篇 |
1993年 | 205篇 |
1992年 | 164篇 |
1991年 | 192篇 |
1990年 | 164篇 |
1989年 | 134篇 |
1988年 | 140篇 |
1987年 | 109篇 |
1986年 | 116篇 |
1985年 | 114篇 |
1984年 | 108篇 |
1983年 | 69篇 |
1982年 | 106篇 |
1981年 | 58篇 |
1980年 | 69篇 |
1979年 | 37篇 |
1978年 | 36篇 |
1977年 | 31篇 |
1976年 | 26篇 |
1974年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Genetics in medicine》2022,24(9):1814-1820
Although still in the early stages of development, the advent of fast, high-output, and cost-effective next-generation DNA sequencing technology is moving precision medicine into public health. Before this shift toward next-generation sequencing in public health settings, individual patients met geneticists after showing symptoms and through limited family screening. In the new era of precision public health, everyone is a possible participant in genetic sequencing, simply by being born (newborn screening), by donating blood (biobanking), or through population screening. These initiatives are increasingly offered to individuals throughout their life and more individuals are encountering opportunities to use DNA sequencing. This article raises awareness of these growing areas and calls for different models of public engagement and communication about genomics, including screening asymptomatic populations, obtaining consent for unspecified and unforeseen future uses of genomic data, and managing variants of uncertain significance. Given that such communication challenges loom large, established norms of practice in genomic medicine and research should be reconsidered. 相似文献
3.
4.
5.
Kyung-Suk Suh Suk Kyun Hong Sola Lee Su young Hong Sanggyun Suh Eui Soo Han Seong-Mi Yang YoungRok Choi Nam-Joon Yi Kwang-Woong Lee 《American journal of transplantation》2022,22(1):260-265
Minimally invasive approaches are increasingly being applied in surgeries and have recently been used in living donor hepatectomy. We have developed a safe and reproducible method for minimally invasive living donor liver transplantation, which consists of pure laparoscopic explant hepatectomy and pure laparoscopic implantation of the graft, which was inserted through a suprapubic incision. Pure laparoscopic explant hepatectomy without liver fragmentation was performed in a 60-year-old man with alcoholic liver cirrhosis and hepatocellular carcinoma. The explanted liver was retrieved through a suprapubic incision. A modified right liver graft, procured from his 24-year-old son using the pure laparoscopic method, was inserted through a suprapubic incision, and implantation was performed intracorporeally throughout the procedure. The time required to remove the liver was 369 min, and the total operative time was 960 min. No complications occurred during or after the surgery. The patient recovered well, and his hospital stay was of 11 days. Pure laparoscopic living donor liver transplantation from explant hepatectomy to implantation was performed successfully. It is a feasible procedure when performed by a highly experienced surgeon and transplantation team. Further studies with larger sample sizes are needed to confirm its safety and feasibility.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2022,33(5):572-577.e1
The technical feasibility of the rocket technique was evaluated for patients treated for stroke where the direct aspiration first-pass technique (ADAPT) failed to reach the occlusion site. This single-center retrospective study included data on consecutive patients with a large vessel occlusion of the anterior circulation who underwent mechanical thrombectomy. Of 138 patients, 100 met the inclusion criteria. In 84 patients, a large 0.072-inch inner lumen aspiration catheter was able to reach the occlusion site when deployed with a coaxial microcatheter. In 16 patients, this technique failed, and the microcatheter was replaced with a compliant balloon inflated at the extremity of the aspiration catheter (rocket technique). In 15 of these 16 patients, the rocket technique brought the catheter into contact with the thrombus. In conclusion, when deployment of the ADAPT with a coaxial microcatheter fails to reach the clot site, the rocket technique can safely advance the aspiration catheter to the clot. 相似文献
8.
《European journal of medical genetics》2021,64(12):104345
BackgroundEpidermolysis bullosa (EB) is a genodermatosis characterized by skin fragility and blisters with variable severity. Patients with Dystrophic EB (DEB) or Junctional EB (JEB) mainly present to clinic due to greater functional impairment. Pathogenic sequence variations in COL7A1 are implicated in DEB.ObjectiveWe have tried to decipher the molecular spectrum and genotype phenotype correlation of 21 Indian patients with EB.MethodsNext generation sequencing (NGS) was performed to determine the pathogenic variants. Sanger sequencing was also done for validation of the variants in eleven individuals.ResultsPathogenic variants were detected in 20 individuals (diagnostic yield of 95%). Majority of them (90%) had sequence variation in COL7A1 while two had pathogenic variants in ITGB4 and KRT14 respectively. Out of the 18 patients confirmed to have DEB, 3 had Dominant DEB (DDEB) whereas 15 patients had Recessive DEB (RDEB). Amongst 23 sequence variations identified, 12 were found to be novel (3 were missense, 5 were premature termination codon variants while 4 were splice-site changes).ConclusionGenotype phenotype correlation was noted with milder manifestations in those with dominant inheritance types. Exact molecular diagnosis can be ascertained by NGS in majority of cases. 相似文献
9.
目的 发现四物汤的新药理作用并辨识其有效成分群。方法 于GEO和Cmap数据库获取四物汤和1309个小分子药物的基因表达谱,计算差异表达基因及四物汤与1309个小分子药物的基因表达谱间的相似性,相似性较高的小分子药物的药理作用为四物汤的新药理作用。相似性较高的小分子药物的靶点作为四物汤发挥新药理作用的靶标,利用分子对接技术辨识四物汤的有效成分群。结果 四物汤具有抗乳腺癌的作用,其有效成分群为荭草苷、芍药苷和半乳糖醛酸等,并通过文献调研验证了辨识结果的可靠性。结论 本研究将为扩大四物汤的临床应用范围及质量控制奠定基础,为乳腺癌的治疗提供新方法。 相似文献
10.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor